entrinsic bioscience Overview
- Founded
- 2011
- Status
- Private
- Employees
- 29
- Latest Deal Type
- Accelerator/Inc
- Investors
- 9
entrinsic bioscience General Information
Description
Developer of dietary supplements designed to address critical digestive health problems in humans and animals around the world. The company's supplements provide amino acids and electrolytes that help to manage gastrointestinal (GI) dysfunction that occurs from the treatment of cancer, by rebuilding and protecting the gastrointestinal tract delivering total body hydration, enabling patients to get relief from the side effects caused by chemotherapy or radiation therapy.
Contact Information
Website
Formerly Known As
Entrinsic Health
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- 100 River Ridge Drive
- Suite 206
- Norwood, MA 02062
- United States
+1 (781) 000-0000
entrinsic bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | 000.00 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 28-Aug-2018 | 000.00 | 000.00 | Completed | Generating Revenue | |
| 5. Accelerator/Incubator | 000.00 | Completed | Startup | |||
| 4. Grant | 17-May-2016 | 000.00 | Completed | Startup | ||
| 3. Early Stage VC (Series B) | 04-Mar-2016 | 00.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series A) | 31-Jan-2015 | $5.12M | $5.12M | 000.00 | Completed | Startup |
| 1. Grant | 01-Jan-2015 | $500K | Completed | Startup |
entrinsic bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
entrinsic bioscience Executive Team (15)
entrinsic bioscience Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Brian Fox | entrinsic bioscience | Board Member | 000 0000 |
| Byron Kalogerou JD | McDermott Will & Emery | Board Member | 000 0000 |
| Charlie Raffin | entrinsic bioscience | Board Observer | 000 0000 |
| Charlotte Hubbert Ph.D | Self | Board Member | 000 0000 |
| Daniel Dennison Ph.D | entrinsic bioscience | Chief Technology Officer & Board Member | 000 0000 |
entrinsic bioscience Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialentrinsic bioscience Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| National Space Biomedical Research Institute | Government | 000 0000 | 000000 0 | ||
| Johnson & Johnson | Corporation | Minority | 000 0000 | 000000 0 | |
| Junonia Capital, LLC | Venture Capital | Minority | 000 0000 | 000000 0 | |
| SmartCap | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Enterade Investment Partners | Venture Capital | Minority | 000 0000 | 000000 0 |